Post‐remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre‐ versus post‐VIALE‐A real‐world experience from a predominantly US community setting

Post‐remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre‐ versus post‐VIALE‐A real‐world experience from a predominantly US community setting

Abstract Background This retrospective cohort study used an electronic health record‐derived, de‐identified, US patient‐level database to better understand the real‐world treatment experience, in a predominantly community setting (80.3% of patients), of venetoclax+hypomethylating agents (HMAs) in ro...

Full description

Bibliographic Details
Main Authors: Pankit Vachhani, Esprit Ma, Tao Xu, Melissa Montez, Sarah Worth, Archibong Yellow‐Duke, Wei‐Han Cheng, Michael E. Werner, Jonathan Abbas, William Donnellan
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
acute myeloid leukemia
bone marrow assessment
hypomethylating agents
real‐world
schedule modifications
survival outcomes
Online Access:https://doi.org/10.1002/cam4.6430

Similar Items

Similar Items